ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $4.34bn
- $3.48bn
- $1.07bn
Acadia Pharmaceuticals Inc Expected To Post Earnings Of 5 Cents A Share: Earnings Preview
Brief: Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada
U.S. RESEARCH ROUNDUP-Apollo, Tesla, UDR
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Kinetik Holdings, Motorola Solutions
U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners
U.S. STOCKS ON THE MOVE-Li-Cycle Holdings, Priority Technology, 3M
U.S. STOCKS ON THE MOVE-Madrigal Pharmaceuticals, Coinbase, Fractyl
U.S. STOCKS ON THE MOVE-Carvana, ADM, Oracle
Street View: Acadia Pharma's approved neurological disorder drug in focus
Acadia Pharma down as co to stop trials of antipsychotic drug
U.S. RESEARCH ROUNDUP-Carvana Co, Oracle, Vail Resorts
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (updated)
Brief: Acadia Pharmaceuticals Announces Top-Line Results From Phase 3 Advance-2 Trial Of Pimavanserin
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
U.S. RESEARCH ROUNDUP-Autozone, Constellation Energy, Sterling Infrastructure
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Acadia Pharmaceuticals Q4 EPS USD 0.28 Vs. IBES Estimate USD 0.3
Acadia Pharmaceuticals Inc Expected To Post Earnings Of 30 Cents A Share: Earnings Preview
Culper Research discloses short position in Acadia Pharma (updated)